U.S. PATENT DOCUMENTS									
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear				
,									
	1								

			FOREIGN PATE	NT DOCUMENTS		
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	т¹
L.H.	1	JP 04347162A	12-2002			

		tom (book magazine journal serial symposium catalog etc.) date bade(s). Volunte-issue	
L.H.	2	Bour et al., The Human Immunodeficiency Virus Type 1 CD4 Receptor and its Central Role in Promotion of HIV-1 Infection, Microbiological Reviews, Mr. 1995, Vol. 59, No. 1, p. 63-93	
	3	Communication Pursuant to Article 96(2) EPC dated July 5, 2006, from European Patent Application No. 04 708 416.5	
	4	Lanza et al., "Active immunity against the CD4 receptor by using an antibody antigenized with residues 41-55 of the first extracellular domain. Proceedings of the National Academy of Sciences of the United States of America (Washington, DC), December 1993, Vol. 90, pp. 11683-11687	
	5	Luning et al., "Solid Phase Synthesis of the Fibronectin Glycopeptide V(Gal beta 3GalNAc alpha)THPGY, its Beta Analogue, and the Corresponding Unglycosylated Peptide," Glycoconjugate Journal, 1991 Dec, Vol. 8(6), pp. 450-455	
	6	Seitz et al., Glycopeptide synthesis and the effects of glycosylation on protein structure and activity, Chembiochem 2000, Vol. 1, pp. 214-246	

3163581 113006

Examiner Signature /Louise Humphrey/ Date Considered 06/09/2007

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.